Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT

被引：49
|
作者：
Giesel, Frederik L. [1 ,2 ,3 ]
Will, Leon [1 ]
Kesch, Claudia [4 ]
Freitag, Martin [2 ,5 ]
Kremer, Christophe [1 ]
Merkle, Jonas [1 ]
Neels, Oliver C. [6 ]
Cardinale, Jens [6 ]
Hadaschik, Boris [4 ]
Hohenfellner, Markus [4 ]
Kopka, Klaus [6 ]
Haberkorn, Uwe [1 ,2 ]
Kratochwil, Clemens [1 ]
机构：
[1] Univ Hosp Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Cooperat Unit Nucl Med, Heidelberg, Germany
[3] German Canc Consortium DKTK, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Dept Urol, Heidelberg, Germany
[5] German Canc Res Ctr, Dept Radiol, Heidelberg, Germany
[6] German Canc Res Ctr, Div Radiopharmaceut Chem, Heidelberg, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2018年 / 59卷 / 04期
关键词：
peptides; PET/CT; biochemical recurrence; F-18-PSMA-1007; PSMA-PET; prostate cancer; POSITRON-EMISSION-TOMOGRAPHY; GA-68-LABELED PSMA LIGAND; RADICAL PROSTATECTOMY; RADIATION-DOSIMETRY; MEMBRANE ANTIGEN; BIODISTRIBUTION; DIAGNOSIS; PET/MRI;
D O I：
10.2967/jnumed.117.196329
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. Ga-68-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several F-18-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of F-18-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of F-18-PSMA-1007. Results: F-18-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in F-18-PSMA-1007-positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 F-18-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, F-18-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.
引用
收藏
页码：632 / 635
页数：4
相关论文
共 50 条
  • [41] Biokinetics and radiation dosimetry of [18F]-PSMA-1007
    Hvittfeldt, E.
    Bjoersdorff, M.
    Oddstig, J.
    Svegborn, S. Leide
    Brolin, G.
    Minarik, D.
    Tragardh, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S137 - S137
  • [42] Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
    Zhou, Xing
    Jiang, Xiao
    Liu, Luzhou
    Wang, Xiaoxiong
    Li, Chuan
    Yao, Yutang
    Kou, Ying
    Shen, Jiaqi
    Shen, Taipeng
    Li, Zeng
    Yang, Shengke
    Zhou, Shukui
    Liao, Hong
    Luo, Zhifu
    Wu, Xiaoai
    Chen, Shirong
    Cheng, Zhuzhong
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [43] The cause of high [18F]PSMA-1007 uptake in the urinary bladder in some of the [18F]PSMA-1007 patients: an explorative, retrospective study
    Allach, Y.
    Prive, B.
    van Gemert, W.
    Schilham, M.
    Perk, L. R.
    Gotthardt, M.
    Nagarajah, J.
    Janssen, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S530 - S530
  • [44] Diagnostic accuracy and therapeutic impact of [18F] DCFPyL (PSMA) PET/CT in biochemical recurrence of prostate cancer
    Fernandez, J. Fernandez
    Ibanez, E. Trivino
    Solero, T. Rudolphi
    Navas, D. Rivas
    Fernandez, A. Rodriguez
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S291 - S291
  • [45] Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
    Hoffmann, Manuela A.
    von Eyben, Finn Edler
    Fischer, Nicolas
    Rosar, Florian
    Muller-Hubenthal, Jonas
    Buchholz, Hans-Georg
    Wieler, Helmut J.
    Schreckenberger, Mathias
    CANCERS, 2022, 14 (06)
  • [46] A Robust [18F]-PSMA-1007 Radiomics Ensemble Model for Prostate Cancer Risk Stratification
    Pasini, Giovanni
    Stefano, Alessandro
    Mantarro, Cristina
    Richiusa, Selene
    Comelli, Albert
    Russo, Giorgio Ivan
    Sabini, Maria Gabriella
    Cosentino, Sebastiano
    Ippolito, Massimo
    Russo, Giorgio
    JOURNAL OF IMAGING INFORMATICS IN MEDICINE, 2024,
  • [47] Diagnostic Performance of [18F]PSMA-1007 PET/CT on Hepatocellular Carcinoma: a Prospective Clinical Study
    Michalski, K.
    Reiter, F.
    Kosmala, A.
    Hartrampf, P. E.
    Serfling, S. E.
    Bley, T. A.
    Geier, A.
    Buck, A. K.
    Werner, R. A.
    Weich, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S502 - S502
  • [48] Impact of [18F]PSMA-1007 uptake in prostate cancer using different peptide concentrations: preclinical PET/CT study in mice.
    Watabe, Tadashi
    Soeda, Fumihiko
    Naka, Sadahiro
    Liu, Yuwei
    Horitsugi, Genki
    Neels, Oliver
    Kopka, Klaus
    Tatsumi, Mitsuaki
    Shimosegawa, Eku
    Giesel, Frederik
    Hatazawa, Jun
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [49] Metabolic heterogeneity of human prostate cancer based on [18F]PSMA-1007 and [18F]FDG PET/CT and introducing the Dice Similarity Coefficient as a New Prognostic Parameter
    Kim, D.
    Oh, K.
    Choo, K.
    Kim, D.
    Lee, S.
    Lim, H.
    Hwang, H.
    Choi, Y.
    Lee, M.
    Cho, N.
    Yun, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S521 - S521
  • [50] Role of [18F]-PSMA-1007 PET radiomics for seminal vesicle invasion prediction in men with primary prostate cancer
    Luo, L.
    Gao, J.
    Li, Y.
    Shen, C.
    Duan, X.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S521 - S521
12345